News
NEO
15.72
+3.42%
0.52
Catalyst Watch: Tesla deliveries, Disney board vote, DJT drama and Fortinet event
Volatility watch - Options trading volume is elevated on Trump Media & Technology (DJT) Key data reports due to arrive this week include updates on Tesla deliveries, Disney board vote, and Solventum spin-off. Fortinet will hold its four-day Accelerate 2024 event in New York.
Seeking Alpha · 18h ago
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
NeoGenomics will present key findings from 11 abstracts at the American Association for Cancer Research's 2024 Annual Meeting in San Diego. The company is a leading oncology testing services company. NeoGenomics is focused on transforming cancer care through innovation, precision, and compassion.
Barchart · 2d ago
Weekly Report: what happened at NEO last week (0318-0322)?
Weekly Report · 4d ago
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
NASDAQ · 03/20 16:00
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
NASDAQ · 03/20 13:55
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
NeoGenomics, Inc. Released its 2023 Environmental, Social, and Governance Report. The report highlights progress toward building a more sustainable, diverse, and equitable company. In 2023, women comprised 59.9% of the global workforce. The company recycled 310 tons of waste from its labs in 2023.
Barchart · 03/20 06:00
Commit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using Options
NASDAQ · 03/19 15:57
What 6 Analyst Ratings Have To Say About NeoGenomics
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the U.S. And Switzerland. The company has an average 12-month price target of $20.67. NeoGenomics has an impressive revenue growth rate of 12.15%. Six analysts have provided ratings for the company in the latest quarter.
Benzinga · 03/18 18:00
Weekly Report: what happened at NEO last week (0311-0315)?
Weekly Report · 03/18 11:15
Earnings Scheduled For March 15, 2024
NeoGenomics is expected to report quarterly earnings at $0.17 per share on revenue of $182.13 million. EHang Holdings is also projected to report earnings for its fourth quarter. Other companies reporting before the bell and after the bell include Prestige Consumer and Buckle.
Benzinga · 03/15 09:15
Weekly Report: what happened at NEO last week (0304-0308)?
Weekly Report · 03/11 11:12
Weekly Report: what happened at NEO last week (0226-0301)?
Weekly Report · 03/04 11:15
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
NeoGenomics, Inc. Will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts on March 5th. Members of NeoGenomics’ management team will hold a fireside chat at the conference. The company is a leading oncology testing services company.
Barchart · 03/01 06:05
Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know
NASDAQ · 02/28 14:55
NeoGenomics Is Maintained at Overweight by Piper Sandler
Dow Jones · 02/26 15:02
NeoGenomics Price Target Raised to $20.00/Share From $18.00 by Piper Sandler
Dow Jones · 02/26 15:02
Piper Sandler Maintains Overweight on NeoGenomics, Raises Price Target to $20
Benzinga · 02/26 14:52
Weekly Report: what happened at NEO last week (0219-0223)?
Weekly Report · 02/26 11:28
U.S. RESEARCH ROUNDUP-Elf Beauty, Moderna, Zscaler
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Elf Beauty, Moderna, and Zscaler are among the companies. Analyst: Elf Beauty raises target price to $225 from $212; Moderna cuts to reduce from hold.
Reuters · 02/26 07:57
NeoGenomics Launches Performance-Based Stock Incentive Plan
TipRanks · 02/24 15:06
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.